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ABSTRACT
Candida glabrata complex includes three species identified through molecular biology 
methods: C. glabrata sensu stricto, C. nivariensis and C. bracarensis. In Mexico, the 
phenotypic methods are still used in the diagnosis; therefore, the presence of C. nivariensis 
and C. bracarensis among clinical isolates is still unknown. The aim of this study was to 
evaluate the utility of a multiplex PCR for the identification of the C. glabrata species 
complex. DNA samples from 92 clinical isolates that were previously identified through 
phenotypic characteristics as C. glabrata were amplified by four oligonucleotides (UNI-5.8S, 
GLA-f, BRA-f, and NIV-f) that generate amplicons of 397, 293 and 223-bp corresponding 
to C. glabrata sensu stricto, C. nivariensis, and C. bracarensis, respectively. The amplicon 
sequences were used to perform a phylogenetic analysis through the Maximum Likelihood 
method (MEGA6), including strains and reference sequences of species belonging to 
C. glabrata complex. In addition, recombination and linkage disequilibrium were estimated 
(DnaSP version 5.0) for C. glabrata sensu stricto isolates. Eighty-eight isolates generated a 
397-bp fragment and only in one isolate a 223-bp amplicon was observed. In the phylogenetic 
tree, the sequences of 397-bp were grouped with C. glabrata reference sequences, and the 
sequence of 223-bp was grouped with C. bracarensis reference sequences, corroborating 
the PCR identification. The number of recombination events for the isolates of C. glabrata 
sensu stricto was zero, suggesting a clonal population structure. Three isolates that did not 
amplify any of the expected fragments were identified as Saccharomyces cerevisiae through 
the sequencing of the D1/D2 domain region within the 28S rDNA gene. The multiplex PCR 
is a fast, cost-effective and reliable tool that can be used in clinical laboratories to identify 
C. glabrata complex species.
KEYWORDS: Candida glabrata complex. Candida bracarensis. Candida nivariensis. 
Multiplex PCR. Candidiasis. Mexico.
INTRODUCTION
Candidiasis is the most frequent opportunistic mycosis in the world. Candida 
albicans is the main agent of candidiasis, but Candida glabrata has emerged as 
the second most important agent of invasive candidiasis in Central and Northern 
Europe and in the United States; however, in some Asian, African and Latin 
American countries, it ranks third or fourth place1. In Mexico, the etiologic 
diversity of invasive candidiasis is similar to that reported in other countries, 
where C. albicans is followed by the C. glabrata complex, C. krusei, C. tropicalis 
and the C. parapsilosis complex causes more than 90% of cases, whereas 
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C. guilliermondii, C. lipolytica, C. famata, C. zeylanoides, 
C. utilis, C. rugosa and C. boidinii are infrequent agents2,3. 
The clinical relevance of the emergence of the C. glabrata 
complex as a frequent pathogen lies in the fact that this 
complex includes three species: C. glabrata sensu stricto, 
Candida bracarensis and Candida nivariensis4-6, which 
can cause similar clinical manifestations although they are 
genetically diverse and differ regarding virulence factors 
and susceptibility to antifungals3,7-10. Therefore, the correct 
identification of the species of C. glabrata complex can 
lead to the appropriate choice of antifungal therapy. The 
identification of these species is not easy using phenotypic 
methods; thus, molecular tests have been developed11-18. 
Among these tests, amplification and sequencing of the 
internal transcribed spacer (ITS) and the D1/D2 domain 
of the large subunit rRNA gene regions stand out4,18-22, as 
well as the amplification of gene fragments with specific 
oligonucleotides that allow an easy differentiation of species 
based on the amplicon molecular weight23,24. However, in 
many clinical laboratories, particularly in Latin America, 
molecular tests are still not used due to their costs as well 
as their methodological complexities, which has led to the 
erroneous identification of C. nivariensis and C. bracarensis 
as C. glabrata among clinical isolates. 
The aim of this work was to evaluate the usefulness of a 
multiplex PCR assay (targeting the ITS1 region and the 5.8S 
ribosomal RNA gene) for the identification of the species 
of C. glabrata complex and to confirm the multiplex PCR 
results through a phylogenetic analysis. 
MATERIAL AND METHODS
Clinical isolates and culture conditions
Ninety-two clinical isolates of the C. glabrata complex 
(Cgl-1 to Cgl-92) were included in this study. The isolates 
were obtained from vaginal exudates, blood samples, 
biopsies, semen samples, abscesses, peritoneal dialysis 
fluid and catheter tips collected in two tertiary hospitals 
(1 and 2) located in Mexico City, during the period of 
January-June 2017. Sixty-five isolates (Cgl-1 to Cgl-65) 
were obtained from hospital 1, and twenty-seven (Cgl-66 
to Cgl-92) from hospital 2. Each isolate was recovered from 
a single patient. All isolates were previously identified by 
the automated system VITEK® 2 Compact (bioMeriux, 
France) as C. glabrata, with 93-98% probability of 
identification. C. glabrata ATCC 2001,  C. bracarensis 
Cb-1 and ExV75 were included as reference strains. The 
Cb-1 strain was identified by proteomics through the 
MALDI-TOF MS spectrometry (score value 2.1), and was 
kindely provided by Dr. Rosa Areli Martínez Gamboa, 
Instituto Nacional de Ciencias Médicas y de la Nutrición 
“Salvador Zubirán”, Mexico City. The ExV75 strain was 
identified by sequencing the ITS region and reported by 
Trevino-Rangel et al.25.
Isolates were grown in Sabouraud agar containing 
chloramphenicol, at 28 °C. Yeasts were kept at room 
temperature in a saline solution (NaCl 0.8%).
Extraction of genomic DNA
Yeasts were cultured in YEPG medium (1% yeast 
extract, 2% peptone, 2% glucose), cells were harvested by 
centrifugation and washed three times with sterile distilled 
water. DNA from the yeasts was extracted and purified 
using the Yeast DNA Preparation kit (Jena Bioscience, GE), 
following the manufacturer’s instructions. DNA samples 
were stored at 4 °C.
PCR
DNA from the yeasts was amplified through multiplex 
PCR, using the primers designed by Romeo et al.23. 
The reaction mixture (25 μL) contained: 1X PCR 
buffer, 100 pmol/μL of each oligonucleotide (UNI-5.8S 
5’-ACCAGAGGGCGCAATGTG-3’, GLA-f 5’-CGGTTG 
GTGGGTGTTCTGC-3’, BRA-f 5’-GGGACGGTAAG 
TCTCCCG-3’, NIV-f 5’-AGGGAGGAGTTTGTATCT 
TTCAAC-3’) (Sigma-Aldrich, USA), 200 μM of each 
dNTP (Jena Bioscience), 2.5 mM MgCl2, 1 U Taq DNA 
polymerase (Jena Bioscience), and 10 ng of genomic 
DNA. As a negative control, sterile Milli-Q® water (Merck 
Millipore, USA) was included. Reactions were carried 
out in a thermocycler T100™ (Bio-Rad, Laboratories, Inc., 
USA). 
The PCR cycles parameters were as follows: preheating 
at 95 ° C for 5 min; then 34 cycles of 94 °C for 30 s, 60 °C 
for 40 s and 72 °C for 50 s, and a final extension at 72 °C 
for 10 min. Amplicons were analyzed by electrophoresis in 
1.7% agarose gels (Pronadisa, ES) stained with 3X GelRed™ 
(Biotium, USA). The electrophoresis was performed in TBE 
(45 mM Tris-Base, 45 mM boric acid, 1 mM EDTA, pH 8.3) 
at 100 V for approximately 45 min. A 100-bp DNA molecular 
size marker was used (Jena Bioscience). Amplified DNA 
fragments were visualized in a UV transilluminator and 
then documented (Gel DocTM EZ Documentation System, 
Bio-Rad Laboratories). The expected molecular weights of 
the amplification products were 397, 293 and 223-bp for 
C. glabrata sensu stricto, C. nivariensis, and C. bracarensis, 
respectively. All amplicons were sequenced in both directions 
at the Genomic Services Unit in LANGEBIO (CINVESTAV, 
Mexico). 
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Sequences analysis
All DNA sequences from the isolates were edited with 
the program BioEdit ver. 7.2.5.26. Subsequently, they were 
analyzed with the BLAST (Basic Local Alignment Search 
Tool) program27 available at www.blast.ncbi.nlm.nih.gov/
blast.cgito verify the identity, similarity and “e-value” 
between sequences. 
Phylogenetic analysis 
All sequences were aligned using the Muscle algorithm 
within MEGA6 with default options28. The statistical method 
of Maximum Likelihood was used, a phylogeny test that 
includes the bootstrap method with 1,000 pseudo replicates; 
then, replicates were analyzed with the MEGA6 program28. 
As a reference, sequences of C. glabrata complex deposited 
in GenBank (C. bracarensis AY589573.2 and MF187327.1, 
C. nivariensis AY620957.1, C. glabrata AY198398.1)23 
were included for comparisons. A sequence of C. albicans 
(JN882343.1) was used as an outgroup. 
Recombination detection and linkage disequilibrium
The recombination and linkage disequilibrium was 
calculated (DnaSP version 5.0)29. The ZZ statistic30 was used 
to verify the effect of intragenic recombination on nucleotide 
variation by analyzing the level of linkage disequilibrium.
RESULTS
PCR
From the total of 92 isolates, 88 amplified a 397-bp 
fragment, compatible with C. glabrata sensu stricto; 
whereas only one (Cgl-60), showed a 223-bp amplicon, 
suggestive of C. bracarensis. The reference strains (ATCC 
2001, Cb-1 and ExV75) amplified the expected fragments 
(Figure 1). None of the isolates amplified a 293-bp 
fragment, corresponding to C. nivariensis. 
Sequence analysis
The 397-bp sequences (accession no: MK583352 
– MK583407 and MK583409 – MK583440) analyzed 
by BLAST revealed an identity and similarity of 100% 
(“e-value” equal to zero) with partial sequences of the 
ITS1-5.8S-ITS2 region from C. glabrata (gb|MK026347.1, 
gb|MH699024.1, gb|LC389240.1, gb|LS398123.1, 
gb|MG599239.1, gb|MH016268.1, gb|MF033154.1, 
gb|LC317501.1).
The 223-pb sequence analyzed by BLAST (from 
the isolate Cgl-60, accession no: MK583408) showed 
100% identity and similarity (“e-value” equal to 2e-111) 
with partial sequences of the ITS1-5.8S-ITS2 region 
from C. bracarensis (gb|JN882340.1, gb|GU199439.1, 
gb|GU199438.1, gb|NR136973.1, gb|MF084287.1, 
gb|MF187327.1, gb|KP674715.1, gb|KP131680.1).
Three isolates (Cgl-2, Cgl-28, and Cgl-32) showed 
no amplification even after the testing of different 
DNA concentrations. Therefore, a region of the 
D1/D2 domain of the 28S rDNA gene was amplified 
and sequenced with the universal oligonucleotides NL1 
(5’-GCATATCAATAAGCGGAGGAAAAG-3’) and 
NL4 (5’-GGTCCGTGTTTCAAGACGG-3’)31. A 588-bp 
amplicon was obtained from the three isolates. The BLAST 
analysis of these sequences showed 100% identity and 
similarity with the sequence of Saccharomyces cerevisiae 
gb|LC334458.1, corresponding to the 28S ribosomal RNA 
region.
Phylogenetic analysis
The phylogenetic tree showed three groups supported by 
a 99% bootstrap: group I included all isolates that amplified 
the 397-bp fragment and reference sequences of C. glabrata 
distributed in three subgroups. The subgroup Ia included 
the majority of isolates from hospital 1; the subgroup Ib 
included most isolates from hospital 2and the subgroup Ic 
included three isolates from hospital 1. The group II included 
the reference sequence (AY620957.1) of C. nivariensis and 
group III included that single isolate (Cgl-60), as well as 
the reference sequences (MF187327.1, AY589573.2, Cb-1 
and ExV75) corresponding to C. bracariensis (Figure 2).
Figure 1 - Electrophoresis of the multiplex-PCR for the 
identification of clinical isolates of the Candida glabrata complex. 
M: molecular weight marker 100-bp; lane 1: Candida glabrata 
ATCC® 2001™ strain; lane 2: Candida bracarensis Cb-1 strain; 
lane 3: Candida bracarensis ExV75 strain; lane 4: isolate Cgl-
59; lane 5: isolate Cgl-61; lane 6: isolate Cgl-63; lane 7: isolate 
Cgl-90; lane 8: isolate Cgl-92; lane 9: negative control (sterile 
water instead of DNA). 
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Recombination detection and linkage disequilibrium
The ZZ value for C. glabrata sensu stricto isolates 
from hospital 1 was 0.0308 (P<0.001) and 0.0000 for 
the ones coming from hospital 2, considered statistically 
significant after the Bonferroni procedure; meanwhile, the 
minimum number of recombination events Rm was 0 for 
both hospitals. These results suggest that the isolates have 
a clonal mode of reproduction. 
DISCUSSION
Although C. albicans remains the most isolated 
species, C. glabrata has emerged as a common agent 
of superficial and invasive candidiasis3. From the report 
of C. bracarensis and C. nivariensis as closely related 
species to C. glabrata, there have been several molecular 
studies in the United States, Europe and Asia, in which 
the existence of C. bracarensis and C. nivariensis has 
been reported. In addition, these species are potentially 
resistant to fluconazole, and have been wrongly identified as 
C. glabrata through conventional methods7,24,32-36. In Latin 
America, the presence of C. bracarensis and C. nivariensis 
is little known10,37 due to the fact that the identification of 
Candida spp. is carried out on a routine basis associated 
with phenotypic methods, such as API ID32C, API20C AUX 
V5.0 (bioMerieux), or VITEK® 2 Compact24,25,36. However, 
these methods fail to differentiate among species belonging 
to C. glabrata33 complex, thus the use of molecular methods 
is required. Although many molecular markers have been 
reported for the identification of species within C. glabrata 
complex, they have not yet been implemented in clinical 
laboratories due to their complexity, high cost of dedicated 
equipment, or because they have not been validated. We 
report in this study the usefulness of a multiplex PCR assay, 
which allowed us to distinguish C. glabrata, C. bracarensis 
and C. nivariensis using four oligonucleotides directed to 
the ITS1-5.8S ribosomal RNA region23. 
From the 92 studied isolates that were identified as 
C. glabrata through the VITEK® 2 Compact system, 
95.6% confirmed the identification as C. glabrata sensu 
stricto, based on the amplicon size, the high percentage of 
identity and similarity revealed in the BLAST analysis, as 
well as their grouping in the phylogenetic tree, where they 
were clearly related to a reference sequence of C. glabrata, 
with a suitable bootstrap value. Likewise, the 99% identity 
and similarity of the 223-bp fragment and its grouping 
to the reference sequences of C. bracarensis, showed 
that the isolated Cgl-60 corresponds to C. bracarensis. 
This isolate was obtained from a vaginal exudate of a 
symptomatic woman, coinciding with the site of isolation 
in other reports2,35, although it is important to mention that 
C. bracarensis has also been isolated from stool samples, 
sputum, blood and urine samples32,37,38. In the same 
way, other studies failed to find C. nivariensis probably 
because this is the less frequent species of the C. glabrata 
complex7,24,34,39. 
The BLAST analysis of the sequences of the D1/D2 
region of the 28S rDNA gene obtained from the Cgl-2, 
Cgl-28 and Cgl-32 isolates that were not amplified by the 
multiplex PCR demonstrated that they do not correspond to 
the C. glabrata complex but to S. cerevisiae. These results 
highlight two important aspects: 1) the specificity of the 
multiplex PCR, as it managed to differentiate between two 
phylogenetically related yeasts (C. glabrata complex and 
S. cerevisiae); 2) although the vaginal infections caused by 
S. cerevisiae are rare, they must be taken into account in 
the differential diagnosis, particularly in women with risk 
factors for infection (previous treatment with corticosteroids 
or broad-spectrum antibiotics, and high-level exposure to an 
environmental source of S. cerevisiae)40. The isolates Cgl-2, 
Cgl-28, and Cgl-32 were obtained from women subjected 
to prolonged treatment with broad-spectrum antibiotics.
The findings of this study showed that four isolates 
(Cgl-2, Cgl-28, Cgl-32, and Cgl-60) had been misidentified 
as C. glabrata with a high level of probability (98-100%) 
Figure 2 - Maximum Likelihood (ML) tree obtained from the ITS1 
region-5.8S ribosomal RNA gene sequences of the Candida 
glabrata clinical isolates. The branch support was inferred by a 
non-parametric bootstrap for ML analysis. As the outgroup, a 
sequence of C. albicans (JN882343.1) was included.
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because the VITEK system® 2 Compact is not the most 
suitable method for the identification of C. glabrata36,41. 
The phylogeny constructed with the sequences from the 
isolates confirmed the identification by PCR; the clustering 
corroborated that 88 isolates corresponded to C. glabrata 
sensu stricto, and one to C. bracarensis. Furthermore, the 
data obtained from the linkage disequilibrium analysis and 
the recombination of C. glabrata isolates from hospitals 
1 and 2 suggested the existence of a clonal population 
structure as shown by Lott et al.42. These results indicate 
the permanence and dissemination of one clone, which 
could represent an advantage since some researchers have 
speculated that the predominance of one genotype may have 
selective ecological benefits such as the decrease of virulent 
strains and of resistance to antifungal agents43.
Based on the results obtained in this study, we 
recommend the multiplex PCR proposed by Romeo et al.23 
as a cost-effective, simple, fast and reliable tool for the 
identification of clinical isolates of the C. glabrata species 
complex. Although it is important to note that the cultivation 
of yeasts is still necessary to determine the susceptibility 
to antifungals, the combination of multiplex PCR and 
culture will contribute to a specific diagnosis, as well as 
to the understanding of the epidemiology and pathogenic 
relevance of these yeasts.
 
CONCLUSION
The multiplex PCR with oligonucleotides UNI-5.8S, 
GLA-f, BRA-f and NIV-f is an accessible, reliable and fast 
tool that can be used routinely in clinical laboratories to 
identify the species of the C. glabrata complex.
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